纳武利尤单抗治疗晚期肾细胞癌：临床实践考量
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
作者信息
Joseph Richard W, Chatta Gurkamal, Vaishampayan Ulka
机构信息
Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Clinical Chief for Genitourinary Medicine, Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY.
出版信息
Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2.
Abstract
BACKGROUND
Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy.
METHODS AND PURPOSE
This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.
摘要
背景
纳武单抗是晚期肾细胞癌患者的一种重要的新治疗选择，与血管内皮生长因子靶向治疗相比，其作用机制不同。它是一种程序性死亡1免疫检查点抑制剂抗体，其反应模式、疗效和安全性与传统的抗血管生成或雷帕霉素哺乳动物靶点抑制治疗不同。
方法与目的
本述评讨论并评估了现有文献中纳武单抗的临床经验，并提出了在晚期肾细胞癌中使用纳武单抗免疫治疗以优化临床管理的实际考虑因素。
相似文献
1
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2.
2
The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Expert Rev Anticancer Ther. 2016 Jun;16(6):577-84. doi: 10.1080/14737140.2016.1184980. Epub 2016 May 17.
3
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
Drug Des Devel Ther. 2017 Apr 11;11:1175-1182. doi: 10.2147/DDDT.S110209. eCollection 2017.
4
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151.
5
Nivolumab in the treatment of advanced renal cell carcinoma.
Future Oncol. 2018 Jul;14(17):1679-1689. doi: 10.2217/fon-2017-0533. Epub 2018 Feb 20.
6
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Drugs. 2018 Sep;78(14):1443-1457. doi: 10.1007/s40265-018-0970-y.
7
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1089-96. doi: 10.1080/17425255.2016.1214713. Epub 2016 Jul 29.
8
Update on immunotherapy for renal cancer.
Medwave. 2021 Jun 4;21(5):e8202. doi: 10.5867/medwave.2021.05.8202.
9
Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.
Urology. 2016 Mar;89:8-9. doi: 10.1016/j.urology.2015.12.003. Epub 2015 Dec 23.
10
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.
引用本文的文献
1
The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report.
Cureus. 2022 Sep 28;14(9):e29680. doi: 10.7759/cureus.29680. eCollection 2022 Sep.
2
A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma.
BMC Cancer. 2021 Jul 19;21(1):831. doi: 10.1186/s12885-021-08559-0.
3
Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Int J Mol Sci. 2021 Jun 11;22(12):6290. doi: 10.3390/ijms22126290.
4
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.
Front Oncol. 2020 Aug 21;10:1400. doi: 10.3389/fonc.2020.01400. eCollection 2020.
5
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
BMJ. 2018 Sep 10;362:k3529. doi: 10.1136/bmj.k3529.
6
Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.
Cell Metab. 2018 Jun 5;27(6):1263-1280.e6. doi: 10.1016/j.cmet.2018.04.009. Epub 2018 May 10.
7
An Immune Atlas of Clear Cell Renal Cell Carcinoma.
Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016.
本文引用的文献
1
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Lancet Oncol. 2016 Jul;17(7):994-1003. doi: 10.1016/S1470-2045(16)30125-5. Epub 2016 Jun 6.
2
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.
3
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.
4
Treatment of Advanced Renal-Cell Carcinoma.
N Engl J Med. 2016 Mar 3;374(9):889-90. doi: 10.1056/NEJMc1515613.
5
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
6
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.
N Engl J Med. 2015 Nov 5;373(19):1872-4. doi: 10.1056/NEJMe1511252. Epub 2015 Sep 25.
7
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
8
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14.
9
Pseudoprogression and Immune-Related Response in Solid Tumors.
J Clin Oncol. 2015 Nov 1;33(31):3541-3. doi: 10.1200/JCO.2015.61.6870. Epub 2015 Aug 10.
10
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Biomed Res Int. 2015;2015:367354. doi: 10.1155/2015/367354. Epub 2015 Jun 16.
Zotero 插件